Alpidem

Summary

Alpidem (CHEMBL54349) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 404.3 Da · C21H23Cl2N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL54349
Name	Alpidem
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54897
Molecular formula	C21H23Cl2N3O
Molecular weight	404.3
InChIKey	JRTIDHTUMYMPRU-UHFFFAOYSA-N

SMILES: CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl

IUPAC name: 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide

Also known as: Alpidem, alpidem, ALPIDEM, SID144207142, SID170466634

Patent coverage: 451 distinct patent families (1,700 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: GABA-A receptor; anion channel, Bile salt export pump, Adenosine receptor A1, Mu-type opioid receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Albumin, Nuclear receptor subfamily 1 group I member 2, Gamma-aminobutyric acid receptor subunit alpha-1, Translocator protein, Translocator protein, Bile salt export pump.

Bioactivity

ChEMBL activities: 24 potent at pChembl ≥ 5 of 32 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P16257	9.3	Ki	0.5	nM	CHEMBL_ACT_10958138
P16257	9.3	Ki	0.5	nM	CHEMBL_ACT_1802395
TSPO	9.3	Ki	0.5	nM	CHEMBL_ACT_19306678
P16257	9.3	Ki	0.5	nM	CHEMBL_ACT_2375850
TSPO	9.3	Ki	0.5	nM	CHEMBL_ACT_24685956
TSPO	9.3	Ki	0.5	nM	CHEMBL_ACT_24986590
P16257	9.3	IC50	0.5	nM	CHEMBL_ACT_24986617
P16257	8.15	Ki	7	nM	CHEMBL_ACT_519472
P16257	8.15	IC50	7	nM	CHEMBL_ACT_994801
P16257	8.1	IC50	7.9	nM	CHEMBL_ACT_1124515
TSPO	8.1	IC50	7.9	nM	CHEMBL_ACT_19306679
P16257	8.1	Ki	7.9	nM	CHEMBL_ACT_24685965
P62813	7.7	AC50	20	nM	CHEMBL_ACT_25208044
O09028	7.58	IC50	26	nM	CHEMBL_ACT_1124514
O09028	7.55	IC50	28	nM	CHEMBL_ACT_994802
P62813	7.37	AC50	43.1	nM	CHEMBL_ACT_25130776
NR1I2	6.72	AC50	191.8	nM	CHEMBL_ACT_25188304
NR1I2	6.32	AC50	484.4	nM	CHEMBL_ACT_25224421
ALB	5.7	Kd	2000	nM	CHEMBL_ACT_20657789
ABCB11	5.32	AC50	4800	nM	CHEMBL_ACT_25127088
ABCB11	5.04	IC50	9200	nM	CHEMBL_ACT_15460409
ABCB11	5.04	IC50	9200	nM	CHEMBL_ACT_18052000
ABCB11	5.04	IC50	9155	nM	CHEMBL_ACT_18081046
ABCB11	5.04	IC50	9200	nM	CHEMBL_ACT_22396463

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).